17983-30-1

Basic information

• Product Name: 3-oxocyclohexanecarbonitrile
• Synonyms: 3-oxocyclohexanecarbonitrile
• CAS NO: 17983-30-1
• Molecular Formula: C₇H₉NO
• Molecular Weight: 123.15246
• Mol File: 17983-30-1.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 3-oxocyclohexanecarbonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 3-oxocyclohexanecarbonitrile(17983-30-1)
• EPA Substance Registry System: 3-oxocyclohexanecarbonitrile(17983-30-1)

Safety Data

• Hazardous Substances Data: 17983-30-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3-oxocyclohexanecarbonitrile is used as a key intermediate in the synthesis of various pharmaceuticals for its ability to facilitate the creation of complex molecular structures. Its reactivity allows for the development of new drugs with specific therapeutic properties.
Used in Agrochemical Industry:
In the agrochemical sector, 3-oxocyclohexanecarbonitrile is utilized as a precursor in the production of pesticides and other crop protection agents, leveraging its chemical properties to enhance the effectiveness and selectivity of these products.
Used in Organic Synthesis:
3-oxocyclohexanecarbonitrile is employed as a versatile reactant in organic synthesis, serving as a starting material for the preparation of a broad range of organic compounds. Its participation in numerous chemical reactions makes it an indispensable tool for chemists working on the development of new molecules.
Used in Fine Chemicals Production:
3-oxocyclohexanecarbonitrile is also used as an intermediate in the production of fine chemicals, where its unique properties contribute to the synthesis of high-value specialty chemicals used in various applications, including fragrances, dyes, and other specialty products.
Safety Precautions:
Given the potential hazards and health risks associated with 3-oxocyclohexanecarbonitrile, it is crucial to adhere to proper handling and safety protocols when working with this chemical. This includes the use of appropriate personal protective equipment, working in well-ventilated areas, and following established safety guidelines to minimize exposure and ensure the well-being of individuals in the laboratory or industrial setting.

Upstream product

• 930-68-7 cyclohexenone 
• 151-50-8 potassium cyanide 
• 74-90-8 hydrogen cyanide 
• 90735-45-8 3,3-Dihydroxy-cyclohexanecarbonitrile 
• 7677-24-9 trimethylsilyl cyanide 
• 100-45-8 3-cyclohexene-1-carbonitrile 
• 19158-51-1 P-toluenesulfonyl cyanide 
• 108-94-1 cyclohexanone 

Downstream Products

• 21531-47-5 3-oxo-cyclohexanecarboxylic acid methyl ester 
• 99407-64-4 (+/-)-methyl 3,3-dimethoxycyclohexanecarboxylate 
• 99407-65-5 (+/-)-pentyl 3,3-di(pentyloxy)cyclohexanecarboxylate 
• 99407-63-3 (+/-)-pentyl 3-oxocyclohexanecarboxylate 
• 87759-72-6 (1R,3S)-cis-3-cyanocyclohexanol 
• 87759-73-7 (1S,3R)-cis-3-cyanocyclohexanol 
• 87759-75-9 (1S,3S)-trans-3-cyanocyclohexanol 
• 90865-33-1 (R)-3-oxo-cyclohexanecarbonitrile 
• 24056-33-5 trans-3-cyanocyclohexanol 
• 24056-33-5 cis-3-hydroxycyclohexanecarbonitrile 
• 99407-62-2 (+/-)-isopropyl 3-oxocyclohexanecarboxylate 
• 952616-39-6 (+/-)-cis-3-benzyloxycarbonylamino-cyclohexane carboxylic acid 

Relevant articles and documents

Preparation of chiral 3-oxocycloalkanecarbonitrile and its derivatives by crystallization-induced diastereomer transformation of ketals with chiral 1,2-diphenylethane-1,2-diol

Chiral 3-oxocycloalkanecarbonitriles were prepared by fractional crystallization and crystallization-induced diastereomer transformation (CIDT) of diastereomeric ketals with (1R,2R)-1,2-diphenylethane-1,2-diol. Investigation of the crystal structures by X

Direct C(sp3)-H Cyanation Enabled by a Highly Active Decatungstate Photocatalyst

A highly efficient, direct C(sp3)-H cyanation was developed under mild photocatalytic conditions. The method enabled the direct cyanation of various C(sp3)-H substrates with excellent functional group tolerance. Notably, complex natural products and bioactive compounds were efficiently cyanated.

Functionalized Polyhydroquinolines from Amino Acids Using a Key One-Pot Cyclization Cascade and Application to the Synthesis of (±)-Δ7-Mesembrenone

Substituted polyhydroquinolines are ubiquitous skeletal cores found in drugs and bioactive natural products. As a new route to access this motif, we successfully developed a one-pot cyclization cascade with high chemocontrol and diastereoselectivity. The sequence generates two cycles, three carbon-carbon bonds, and an all-carbon quaternary center in a highly convergent process. Functionalized polyhydroquinolines and congeners can be accessed from commercially available amino acids. This versatile and robust strategy was applied to the synthesis of (±)-Δ7-mesembrenone.

Polycyclic amide derivative as CDK9 inhibitor, and preparation method and application thereof

The invention belongs to the technical field of polycyclic amide derivatives, and particularly relates to a polycyclic amide derivative as a CDK9 inhibitor, and a preparation method and application thereof. The polycyclic amide derivative shows excellent CDK9 enzyme inhibitory activity, and can be used for preparing drugs for treating cancers, especially hematologic cancers including acute myeloid leukemia, multiple myeloma, chronic lymphocytic leukemia, follicular lymphoma and the like and solid tumors, such as acute myeloid leukemia, multiple myeloma, chronic lymphocytic leukemia and follicular lymphoma, including breast cancer, prostate cancer, ovarian cancer, hepatocellular carcinoma, pancreatic cancer, kidney cancer, stomach cancer, colorectal cancer, lung cancer and the like.

A Comparative Assessment Study of Known Small-Molecule Keap1-Nrf2 Protein-Protein Interaction Inhibitors: Chemical Synthesis, Binding Properties, and Cellular Activity

Inhibiting the protein-protein interaction (PPI) between the transcription factor Nrf2 and its repressor protein Keap1 has emerged as a promising strategy to target oxidative stress in diseases, including central nervous system (CNS) disorders. Numerous non-covalent small-molecule Keap1-Nrf2 PPI inhibitors have been reported to date, but many feature suboptimal physicochemical properties for permeating the blood-brain barrier, while others contain problematic structural moieties. Here, we present the first side-by-side assessment of all reported Keap1-Nrf2 PPI inhibitor classes using fluorescence polarization, thermal shift assay, and surface plasmon resonance - and further evaluate the compounds in an NQO1 induction cell assay and in counter tests for nonspecific activities. Surprisingly, half of the compounds were inactive or deviated substantially from reported activities, while we confirm the cross-assay activities for others. Through this study, we have identified the most promising Keap1-Nrf2 inhibitors that can serve as pharmacological probes or starting points for developing CNS-active Keap1 inhibitors.

Identification and Implementation of Biocatalytic Transformations in Route Discovery: Synthesis of Chiral 1,3-Substituted Cyclohexanone Building Blocks

Several biocatalytic approaches for the preparation of optically pure methyl 3-oxocyclohexanecarboxylates (S)-, (R)-1 and 3-oxocyclohexanecarbonitriles (S)-, (R)-2 have been successfully demonstrated. Screening of reaction-focused enzyme collections was used to identify initial hits using three enzymatic strategies. Reaction optimization and scale-up enabled the production of chiral intermediates for route scouting efforts on scales of up to 100 g. The enzymes applied in these processes (lipases, enoate reductases, and nitrilases) have been shown to be robust catalysts for drug manufacturing and represent a green alternative to conventional methods to access these chiral cyclohexanone building blocks.

3-AMINOMETHYL-1-CYCLOHEXYLAMINE, AND METHOD FOR THE PRODUCTION THEREOF

The present invention relates to 3-aminomethyl-1-cyclohexylamine and to a process for preparation thereof by a) reacting cyclohexenone with hydrogen cyanide in the presence of a basic catalyst, b) reacting the cyclohexanonenitrile obtained in stage a) wit

PROCESS FOR PREPARING CYCLIC DIAMINES

The present invention relates to a process for preparing a cyclic diamine, comprising the reaction of at least one cyclic alkene with a gas mixture (G) comprising dinitrogen monoxide to give at least one cyclic ketone and the subsequent conversion of the

Discovery of 2-chloro-N-((4,4-difluoro-1-hydroxycyclohexyl)methyl)-5-(5-fluoropyrimidin-2-yl)benzamide as a potent and CNS penetrable P2X7 receptor antagonist

Focused SAR studies were carried out around 5-heteroaryl and 1-amide portions of the 2-chlorobenzamide scaffold, resulting in the discovery of a potent, metabolically stable and centrally penetrable antagonist against P2X7 receptor.

Nitrilases catalyze key step to conformationally constrained GABA analogous γ-amino acids in high optical purity

(Chemical Equation Presented) Five- and six-membered carbocyclic γ-amino acids were prepared in high enantiomeric purity by nitrilase-mediated transformation of hitherto unreported γ-amino nitriles. The nitrilases investigated reveal a strong enantioprefe